These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 7867175)

  • 1. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group.
    Parker JO; Amies MH; Hawkinson RW; Heilman JM; Hougham AJ; Vollmer MC; Wilson RR
    Circulation; 1995 Mar; 91(5):1368-74. PubMed ID: 7867175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval.
    Parker JD; Parker AB; Farrell B; Parker JO
    Circulation; 1995 Feb; 91(4):973-8. PubMed ID: 7850984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period.
    Freedman SB; Daxini BV; Noyce D; Kelly DT
    J Am Coll Cardiol; 1995 Feb; 25(2):349-55. PubMed ID: 7829787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the second transdermal intermittent dosing evaluation study (TIDES-II).
    Pepine CJ; Lopez LM; Bell DM; Handberg-Thurmond EM; Marks RG; McGorray S
    J Am Coll Cardiol; 1997 Oct; 30(4):955-61. PubMed ID: 9316524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained antianginal efficacy of transdermal nitroglycerin patches using an overnight 10-hour nitrate-free interval.
    Schaer DH; Buff LA; Katz RJ
    Am J Cardiol; 1988 Jan; 61(1):46-50. PubMed ID: 3122549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Steering Committee, Transdermal Nitroglycerin Cooperative Study.
    Am J Cardiol; 1991 Nov; 68(13):1263-73. PubMed ID: 1951111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefit of transdermal glyceryl trinitrate when used with an eight hour patch-free period.
    Whalley DW; Hellestrand KJ
    Aust N Z J Med; 1990 Oct; 20(5):677-81. PubMed ID: 2126727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina.
    DeMots H; Glasser SP
    J Am Coll Cardiol; 1989 Mar; 13(4):786-95. PubMed ID: 2494240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dosing intervals on the development of tolerance to high dose transdermal nitroglycerin.
    Nabel EG; Barry J; Rocco MB; Mead K; Selwyn AP
    Am J Cardiol; 1989 Mar; 63(11):663-9. PubMed ID: 2493732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal nitroglycerin reduces the frequency of anginal attacks but fails to prevent silent ischemia.
    Rossetti E; Luca C; Bonetti F; Chierchia SL
    J Am Coll Cardiol; 1993 Feb; 21(2):337-42. PubMed ID: 8425995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography.
    Mahmarian JJ; Fenimore NL; Marks GF; Francis MJ; Morales-Ballejo H; Verani MS; Pratt CM
    J Am Coll Cardiol; 1994 Jul; 24(1):25-32. PubMed ID: 8006274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance, rebound, and time-zero effect of nitrate therapy.
    Frishman WH
    Am J Cardiol; 1992 Nov; 70(17):43G-47G; discussion 47G-48G. PubMed ID: 1449099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avoidance of tolerance and lack of rebound with intermittent dose titrated transdermal glyceryl trinitrate. The Transdermal Nitrate Investigators.
    Fox KM; Dargie HJ; Deanfield J; Maseri A
    Br Heart J; 1991 Aug; 66(2):151-5. PubMed ID: 1909152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent or continuous transdermal nitroglycerin: still an issue, or is the case closed?
    Klemsdal TO; Gjesdal K
    Cardiovasc Drugs Ther; 1996 Mar; 10(1):5-10. PubMed ID: 8723164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intermittent (eight hours off) transdermal nitrate therapy in stable angina.
    Akhras F; Hellestrand K; Whalley D; Jackson G
    Int J Cardiol; 1994 Mar; 43(3):251-6. PubMed ID: 8181883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized placebo controlled, double-blind, crossover trial of transdermal nitroglycerin in stable angina pectoris.
    Rezaković DE; Pavicić L; Majacić M
    Eur Heart J; 1988 Jan; 9 Suppl A():73-81. PubMed ID: 3137073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal nitroglycerin in angina pectoris: efficacy of intermittent application.
    Luke R; Sharpe N; Coxon R
    J Am Coll Cardiol; 1987 Sep; 10(3):642-6. PubMed ID: 3114351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of diuretic therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina.
    Parker JD; Parker AB; Farrell B; Parker JO
    Circulation; 1996 Feb; 93(4):691-6. PubMed ID: 8640997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal nitroglycerin patches in angina pectoris. Dose titration, duration of effect, and rapid tolerance.
    Thadani U; Hamilton SF; Olson E; Anderson J; Voyles W; Prasad R; Teague SM
    Ann Intern Med; 1986 Oct; 105(4):485-92. PubMed ID: 3092711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a new transdermal nitroglycerin patch (Deponit 10) for stable angina pectoris.
    Greco R; D'Alterio D; Schiattarella M; Boccia A; Greco L; Marsico F
    Am J Cardiol; 1988 Mar; 61(9):44E-51E. PubMed ID: 3126635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.